Chapter 22: Psychotherapeutic Drugs

Welcome to Last Minute Lecture.

This free chapter overview is designed to help students review and understand key concepts.

These summaries supplement, not replace, the original textbook and may not be redistributed or resold.

For complete coverage, always consult the official text.

Welcome back to the Deep Dive.

I'm glad you're here because today we are going to try to do something, well, something pretty ambitious.

We are going to try to understand the machinery of the human mind.

Or at least the chemical wrenches we can throw into the gears when things start to go wrong.

That's a much better way of putting it.

We're dedicating this entire session to chapter 22 of Brenner and Stevens Pharmacology, sixth edition.

The chapter is titled Psychotherapeutic Drugs.

And honestly, it is one of the densest, most high stakes chapters in the entire book.

High stakes is right.

I mean, we aren't talking about lowering cholesterol or fixing a runny nose here.

Oh no.

We're talking about the very essence of who a person is.

We're talking about schizophrenia, depression, bipolar disorder, ADHD.

These are conditions that can fundamentally alter a person's reality, their mood, their focus.

Exactly.

And just to set the ground rules for everyone listening, for you, our learners, we are going to do a strict, deep analysis of this specific text.

Right.

We aren't wandering off into, you know, pop psychology or experimental therapies that aren't mentioned in the book.

Our mission is to take the mechanisms that Brenner and Stevens describe, which can be a real alphabet soup of receptors and pathways,

and translate them.

To translate them into something you can actually visualize and understand.

We want you to have that aha moment.

We want to move from just memorizing block D2 to really getting why blocking the D2 receptor can quiet the voices in a patient's head.

And we have to do that without oversimplifying.

The text is rigorous, so we need to be rigorous too.

These drugs are incredibly powerful and their side effects can be permanent.

We really owe it to the material to get the details right.

Absolutely.

So let's open up the map for this chapter.

The text starts by categorizing mental illness into two massive buckets.

On one side you have the psychoses.

Right.

And the prototype for psychosis in this chapter is schizophrenia.

This is defined by a fundamental break from reality.

What does that mean exactly?

A break from reality.

It means the brain is generating input that isn't actually there.

So hallucinations.

And the person is holding onto beliefs that are demonstrably false.

We call those delusions.

And in the other bucket we have the affective disorders.

Affect basically means mood.

So these are disorders of emotional regulation.

So you have the crushing lows.

Of depression, yes.

And on the other end the frenetic, sometimes dangerous highs of mania.

And when a patient cycles between those two poles, that's bipolar disorder.

Exactly.

The text actually starts with a little bit of optimism though, doesn't it?

It mentions that the last 50 years have been, well,

revolutionary.

It's a total revolution.

I mean, if you were a clinician back in, say, 1940, you had almost nothing.

Maybe some sedatives, maybe physical restraints.

A pretty bleak picture.

Incredibly bleak.

Today we have drugs that can genuinely give people their lives back.

And the text makes a point that the goal of modern pharmacology isn't just make the symptoms stop.

It's more nuanced.

It's to create agents with higher efficacy and fewer adverse reactions.

We're trying to move away from the sledgehammer approach to something more like a scalpel.

Though as we're going to see, some of these drugs are still pretty blunt instruments.

That's true.

Yeah.

Treatment resistant cases are still a huge, huge hurdle.

But let's not get ahead of ourselves.

Okay, roadmap time.

We are going to start in the deep end with schizophrenia and the antipsychotics.

Then we'll move over to the effective disorders, so the antidepressants and mood stabilizers.

And we'll wrap up with the CNS stimulants used for ADHD.

It's a very logical progression.

You go from dampening an overactive system in schizophrenia to boosting a sluggish system in depression.

And then trying to stabilize a wildly fluctuating system in bipolar.

It all fits together.

All right, let's dive into segment one.

Schizophrenia.

The text throws a number at us right away.

1 % of the population.

Which is just staggering when you think about it.

One in every hundred people.

Yeah.

And the onset is usually young, late teens to early thirties.

Just when life is supposed to be starting.

That's when reality can fracture.

So to understand the drugs, we have to first understand what they're treating.

The text breaks the symptoms down into two categories, which I always found a little confusing in school.

Positive and negative symptoms.

Right.

Because positive usually means good.

Yeah.

You have to throw out the emotional definition of those words entirely.

Think of it more like a math equation.

Positive symptoms are things that are added to the patient's experience.

They are present,

but they shouldn't be.

So the hallucinations, the voices.

Exactly.

Hearing voices, seeing things that aren't there.

Delusions too, like believing the FBI is decoding your messages through the TV.

Agitation.

These are all plus symptoms.

And the text links these added symptoms to a very specific wiring problem in the brain, right?

This is absolutely crucial.

The text links these positive symptoms to excessive neuronal activity in what's called the mesolimbic pathway.

Mesolimbic.

It's a dopamine superhighway deep in the emotional center of the brain.

For these patients, the traffic is just moving way, way too fast.

Okay.

So mesolimbic pathway equals positive symptoms equals too much dopamine.

Got it.

So what about the negative symptoms?

So these are the subtracted behaviors, things that should be there in a healthy person, but are now missing.

Like motivation, for example.

Exactly.

The text lists abolition, which is just a clinical term for a profound lack of motivation,

and anhedonia, which is the inability to feel pleasure from anything.

That sounds awful.

It is.

You also see social withdrawal, apathy, something called allergia, which is a poverty of speech.

The person just, well, they seem to fade away.

Their personality vanishes.

And anatomically, this is a different problem, a different pathway.

A totally different problem.

While that mesolimbic system is overheating,

the mesocortical pathway is doing the opposite.

And where does that one go?

It connects to the frontal lobes, the executive thinking part of the brain.

And that pathway is actually underactive.

It has insufficient dopamine activity.

Okay, hold on.

That seems like a massive contradiction for a pharmacologist.

You have one part of the brain screaming too much dopamine, and another part whispering, not enough dopamine.

Yes.

How on earth do you treat that with a single pill?

That is the central challenge of antipsychotic therapy.

And the text is very honest about it.

The drugs we have, especially the older ones, are really good at quieting that mesolimbic system.

They fix the positive symptoms, but they're often terrible at fixing the mesocortical system.

They don't help the negative symptoms.

And in fact, because those negative symptoms are harder to treat, they're associated with a much poorer long -term prognosis.

This all leads us to the core theory of the chapter, the dopamine hypothesis.

It's the bedrock, really.

The hypothesis, in its simplest form, just states that schizophrenia results primarily from abnormalities in dopamine neurotransmission.

But the way we figured this out is a great story of pharmacological reverse engineering.

We didn't start by looking at brains, did we?

No, not at all.

We started with the drugs, we found chemicals that worked, and then we asked, okay, what are you doing in the brain?

And the answer was surprisingly clear.

It was almost spooky.

The text describes a correlation, and if you look at the graph in figure 22 .1, you can see it.

Imagine the x -axis is how tightly a drug binds to the dopamine D2 receptor in a test tube.

Okay.

And the y -axis is the clinical potency, how small of a dose you need to give a patient to get an effect.

The correlation is a perfect straight line.

So if a drug grabs onto that D2 receptor like a pit bull, you only need a tiny, tiny dose to stop the hallucination.

Precisely.

And if it binds loosely, you need a massive dose.

This told scientists, okay, the therapeutic effect must be happening because we are blocking D2 receptors.

And therefore, the disease itself must be caused by too much D2 stimulation.

Exactly.

And there was a flip side to that evidence too, which involved amphetamines.

Right.

Drugs that do the opposite.

Yes.

If you give a healthy person a massive dose of amphetamines or cocaine drugs that just flood the brain with dopamine, what happens?

They get paranoid.

They get paranoid.

They start hearing things.

They develop what we call a drug -induced psychosis that looks almost identical to paranoid schizophrenia.

So if flooding the brain with dopamine causes madness, blocking dopamine should cure it.

It's a very logical conclusion.

It is.

And the text mentions that PT scans have largely confirmed this, at least to some degree.

What's a PT scan?

Positron emission tomography.

It lets you actually visualize the receptors in the brains of living patients.

And it confirms that split we talked about.

They often see increased D2 receptor density in parts of the basal ganglia.

The overactive system.

And decreased density in the prefrontal cortex.

The underactive system.

It fits the model.

Before we jump into the specific drugs, I want to talk about the case of the paranoid policeman.

It's in box 22 .3.

And it really grounds all this science in a real -world scenario.

Can you walk us through it?

It's a very startling image, isn't it?

You have a 24 -year -old police officer.

And remember, that age is classic for a first psychotic break.

Right in the prime of his life.

He barricades himself in an interrogation room.

He's waving his service weapon around.

He's screaming, get out of my head.

That's just pure textbook paranoia.

It is.

He believes there's a conspiracy against him.

But then he also yells that he is immortal.

Which is a delusion of grandiosity.

Exactly.

And then his partner fills in the other details.

He's been wearing dirty clothes.

He hasn't been showering.

So that's the deterioration of self -care.

That's a negative symptom.

It is.

So the emergency services manage to subdue him.

He is in acute danger to himself and others.

The doctors in the ER need to act immediately.

They don't have weeks to wait for therapy to kick in.

No.

They need a chemical restraint.

Fast.

So they reach for haloperidol.

And the text explains why haloperidol specifically.

It's about the pharmacokinetics.

Yes.

You can inject it intramuscularly.

Usually in the thigh or the glute.

It has very high bioavailability and it's absorbed rapidly.

The plasma levels peak in about 20 minutes.

So it's fast.

It's fast.

And it's a high -potency D2 blocker.

It acts to shut down that mesolimbic overload very, very quickly.

It's an emergency break.

So haloperidol is a classic example of our first major class of drugs.

The text calls them typical antipsychotics or first generation.

Right.

But it also mentions an older term you might hear.

Neurolectics.

That sounds intense.

It's a Greek term meaning to seize the nerve.

It was a fitting name for these intense drugs.

They were called that because they didn't just stop hallucinations.

They suppressed all motor activity and emotional expression.

They turned patients into zombies, essentially.

That was the criticism.

Yes.

A chemical straight jacket.

So let's break down the mechanism of these typical agents like haloperidol and the older one,

chlorpromazine.

The defining feature of typical antipsychotics, which you can see in table 22 .1, is that they are pretty indiscriminate blockers of dopamine D2 receptors.

They're dopamine hunters.

They are.

If you look at their binding profile, their affinity for D2 receptors is equal to, or in most cases, much greater than their affinity for any other receptor, like serotonin receptors.

And that explains why they work so well for the positive symptoms.

They block that overactive mesolimbic pathway.

Correct.

But the brain uses dopamine for a lot of other things, too.

It's not just for psychosis.

And that is the tragic trade -off of these drugs.

We want to block dopamine in the limbic system, but these drugs are not geographically specific.

They also block dopamine in the basal ganglia.

Which controls movement.

Which controls all voluntary movement.

So when you block dopamine there, you create what are called extra pyramidal symptoms, or EPS.

You essentially give the patient a drug -induced Parkinson's disease.

A terrible choice to have to make.

This then led to the development of the atypical or second generation antipsychotics.

Yes, drugs like clozapine,

risperidone, elanzapine.

How are they different?

What makes them atypical?

They flip the script on receptor affinity.

Chemically, they have a greater affinity for serotonin 5 -HT2 receptors than they do for dopamine D2 receptors.

Okay, that seems counterintuitive.

Why does blocking serotonin help with the dopamine problem?

It's all about the intricate wiring map of the brain.

In the mesocortical pathway, remember, that's the one going to the frontal lobe where dopamine is too low.

The one causing the negative symptoms.

Exactly.

In that pathway, serotonin actually acts as a brake on dopamine release.

It's an inhibitory signal.

So if these atypical drugs block the serotonin receptors, they're essentially cutting the brake lines.

Which allows more dopamine to flow in that specific area.

Precisely.

By blocking the 5 -HT2 receptors in the cortex, you indirectly increase dopamine release right where you need it most.

And this is thought to be why they can help alleviate the negative symptoms, the apathy, the withdrawal, which the typicals couldn't touch.

Wow.

That is incredibly elegant.

You're blocking dopamine where it's too high in the limbic system, but you're boosting it where it's too low in the cortex by manipulating a completely different neurotransmitter.

It is elegant, but there's a catch.

The text describes a phenomenon called the therapeutic lag.

I was just about to ask about that.

You give the drug, the receptors are blocked within hours, but the patient doesn't actually stop hallucinating for weeks.

Why the delay?

Yeah, if the plug is in the socket, why isn't the power off?

The text explains this with the concept of depolarization blockade.

Yeah.

Imagine you are driving a car and someone clamps a boot on the wheel.

That's the drug blocking the receptor.

Okay.

The engine, which is the presynaptic neuron,

doesn't just stop.

Initially, it revs harder.

It senses the blockage and its internal feedback loop says, hey, I need to send more signal.

So it ramps up dopamine synthesis and release.

So for the first few days, the brain is actively fighting the drug.

It is.

The neuron is firing rapidly, trying to overcome the block.

But eventually after a few weeks, it just can't keep up.

The neuron becomes exhausted.

It enters a state of inactivation called depolarization blockade.

It just gives up.

It basically gives up and stops firing.

And it is that delayed shutdown of the neuron's firing rate that finally correlates with the antipsychotic effect.

It's a war of attrition.

But the text warns that this prolonged blockade leads to a long -term adaptation that can be, well, permanent and dangerous.

This is one of the scariest parts of the chapter for me.

It's called supersensitivity.

If you block a receptor for months or years, the body tries to compensate.

The postsynaptic membrane, the receiving neuron,

essentially says, I'm starving.

I'm not getting enough signal.

So it starts to build more dopamine receptors.

It sprouts them all over its surface.

So it becomes hypersensitive to any little bit of dopamine that might be around.

Hypersensitive is the perfect word.

And that leads us directly into segment three and the long -term adverse effects.

Right.

The text has a massive table, table 22 .2, listing all of these.

Let's start with the movement disorders, the EPS.

Okay.

These are the extra pyramidal symptoms.

They all happen because of that D2 blockade in the basal ganglia, the movement centers.

The text lists three main acute forms.

What's the first one?

First is akathisia.

This isn't just fidgeting.

The text describes it as a profound, torturous, internal restlessness.

The patient feels like their skin is crawling.

They cannot sit still.

I can't even imagine that.

They pace back and forth for hours.

It's often mistaken for agitation from the psychosis.

So what do doctors do?

They up the dose of the antipsychotic, which just makes the akathisia worse.

Oh, that's a vicious cycle.

What's next?

Then there's pseudo -Parkinsonism,

which is exactly what it sounds like.

Drug -induced Parkinson's.

Yes.

Rigid muscles,

bradykinesia, which means slow movement, a shuffling gait, and a resting tremor.

You've chemically induced all the hallmark symptoms of Parkinson's disease.

And the third one sounds absolutely terrifying.

Dystonia.

Dystonia is a sudden, severe, and very painful muscle spasm.

The text gives a couple of classic examples.

One is an oculodgeric crisis.

What on earth is that?

Imagine your eye muscles cramping so hard that your eyeballs are locked, looking straight upward.

You physically cannot look down.

That's horrifying.

Or torticollis, where your neck muscles twist your head to the side and lock it there.

The text notes that the risk for dystonia is highest in young males on high -potency drugs.

Those are all acute.

They happen early in treatment.

But that supersensitivity you mentioned causes the long -term monster.

Tardive dyskinesia.

Yes.

Tardive means late.

Dyskinesia means bad movement.

This typically appears after months, or more commonly years, of treatment.

And what does it look like?

Because those receptors have become so supersensitive,

the muscles start moving on their own.

Completely out of the patient's control.

You see these classic oral and facial movements, lip smacking, tongue protrusion, chewing motions, grimacing.

And the text says it's often irreversible.

Often, yes.

Even if you stop the drug, the receptors remain supersensitive.

And here is the cruelest irony, which the text points out.

If you increase the dose of the antipsychotic, the movements stop.

Wait, why?

That makes no sense.

They stop temporarily.

Because you are overwhelming those supersensitive receptors with a massive fresh blockade.

But that just drives the underlying supersensitivity even further, making the problem worse in the long run.

It's a trap.

Is there any way out of that trap now?

The text mentions a newer drug, valbenazine.

It works through a totally different mechanism.

It inhibits something called VMA2.

It's an enzyme that packages dopamine into vesicles inside the neuron before it gets released.

So valbenazine stops the neuron from loading its dopamine bullets.

So there's just less dopamine being released in the first place.

Exactly.

And if there's less dopamine being released, it doesn't matter how sensitive the receptors are.

There's nothing there to trigger them.

It effectively turns down the volume on the signal itself.

We also need to cover what I call the dirty side effects.

These drugs don't just hit dopamine and serotonin.

They hit everything.

They are absolute shotgun blasts.

Especially the older low -potency ones.

The text lists them out by receptor.

Let's walk through them.

Okay.

They block alpha -1 adrenergic receptors.

That causes your blood pressure to drop when you stand up.

Orthostatic hypotension.

And you get dizzy.

Muscarinic receptors.

Blocking those dries you out completely.

Dry mouth, constipation, blurred vision, urinary retention,

the classic anticholinergic effects.

And histamine receptors.

Blocking H1 histamine receptors causes two things everyone hates.

Deep sedation and massive weight gain.

And then there is one rare but absolutely life -threatening emergency you have to know.

NMS.

Neuroleptic malignant syndrome.

It's rare.

The text says 0 .5 to 1%.

But if you see it, you have to act fast.

What are the signs?

The patient becomes rigid as a board.

Lead pipe rigidity.

Their temperature spikes dangerously high, over 38 or 39 degrees celsius, which is over 100 Fahrenheit.

And their consciousness fades.

It sounds like the whole system is shutting down.

It is.

Their body is basically cooking itself.

You have to stop the drug instantly, get them to an ICU, and cool them down or they will die.

It's a true medical emergency.

Let's look at the specific agents now.

We have the typicals and atypicals.

Among the typicals, the text divides them into low potency and high potency.

Right.

Chlorpromazine is the classic low potency drug.

Because it's relatively weak at blocking dopamine,

you need a high dose to get an effect.

And that high dose means you get more of those dirty side effects.

Exactly.

That high dose spills over and hits all those other receptors.

Histamine, muscarinic, alpha.

So patients on chlorpromazine are typically very sedated, have low blood pressure, and gain a lot of weight.

But they have lower rates of the

And on the other end is haloperidol, high potency.

Haloperidol is a laser for the dopamine D2 receptor.

It binds very tightly.

So you need a very small dose.

Which means less sedation and weight gain.

But the risk of EPS, the rigidity, the tremors, the dystonia, is massive.

It's a direct trade -off.

The book also mentions a non -psychosis use for haloperidol.

Yes, for Tourette syndrome.

It's very effective at suppressing the motor tics and the coprolalia, the compulsive swearing that can come with Tourette's.

Then we move to the atypicals.

Clozapine is the famous one, the prototype.

Clozapine is.

It's a special case.

It is arguably the most effective antipsychotic we have, especially for treatment -resistant patients and for negative symptoms.

But it's dangerous.

It's very dangerous.

It causes a condition called a granulocytosis in about one to two percent of patients.

And that's a drop in white blood cells.

A catastrophic life -threatening drop.

Your immune system essentially disappears.

Patients can die from a simple infection like a cold.

Wow.

That's why anyone on Clozapine needs to have their blood drawn every single week for the first six months of treatment.

It's a huge burden on the patient and the system.

So to avoid that, they made Olanzapine.

Which is basically a chemical analog of Clozapine, but without the granulocytosis risk.

The problem is it causes severe metabolic syndrome.

What does that entail?

Massive weight gain.

It's not uncommon for patients to gain 20, 30, even 40 pounds very rapidly.

It also increases the risk of diabetes and high cholesterol.

And it's very sedating.

How about risperidone?

Risperidone has low sedation, which is a plus.

But of all the atypicals, it has the highest risk of EPS.

It acts a bit more like a typical agent in that regard.

It can also cause cardiac dysrhythmias, specifically QT prolongation.

And the last one I want to ask about is aripiprazole.

The text says its mechanism is unique.

It is.

It's not a full antagonist.

It's what we call a partial agonist.

What does that mean?

Instead of jamming the receptor door shut like a regular antagonist, it just kind of stands in the doorway.

It allows some dopamine activity to get through, but it prevents the massive flood of dopamine that causes psychosis.

So it's a modulator, not a blocker.

A dopamine system stabilizer is another way to think about it.

The text also notes it's sometimes used for irritability associated with autism.

One final crucial warning on all antipsychotics.

The elderly.

Yes.

There's a big FDA black box warning on these.

You should not use these drugs to treat sundowning or dementia -related psychosis in elderly patients.

Why not?

The data shows it significantly increases the risk of stroke and death in that population.

It's a major safety no -go.

Alright, let's take a breath.

That was a deep dive into the psychoses.

Now we are shifting gears completely.

Segment 4.

Effective disorders.

Depression and mania.

We're leaving the dopamine hypothesis behind and entering the world of the biogenic amine hypothesis.

Which means we're not talking about dopamine anymore.

Not primarily.

The theory here is that mood disorders are caused by abnormalities in two different neurotransmitters.

Serotonin, also known as 5 -HT, and norepinephrine, or NE.

The idea is that if you don't have enough serotonin, your brain loses its ability to regulate mood.

That's the essence of it.

The text suggests that serotonin provides the cortex with kind of emotional resilience.

Without enough of it, every negative signal, every setback, feels catastrophic.

There's no buffer.

And the text also gives a little nod to melatonin, specifically for seasonal affective disorder, or SAD.

It does.

It's a neat little connection.

Melatonin, the sleep hormone, normally suppresses serotonin release.

In the winter, you have more hours of darkness, so your brain produces more melatonin.

Which squashes your serotonin levels.

And that can lead to depression.

It's a plausible biological mechanism for why people feel down in the winter.

So the goal of almost all antidepressants is to boost these neurotransmitters.

The main mechanism is reuptake inhibition.

I love the vacuum cleaner analogy for this.

It's the best way to visualize it.

Imagine the synapse, that tiny gap between two neurons.

The presynaptic neuron, the sender, releases serotonin into the gap.

Let's call the serotonin molecules dust.

Okay, so dust floating in the gap.

The dust floats around, hits the receptors on the other side, and does its job.

Then, a special transporter protein, let's call it CERT, for the serotonin transporter, acts like a little vacuum cleaner.

Its job is to suck the serotonin back up into the neuron to be recycled.

And the antidepressant drug acts like a plug for the vacuum.

Exactly.

A drug like an SSRI physically jams the nozzle of the vacuum cleaner.

The serotonin can't get sucked back up.

So it stays in the gap longer?

It stays in the gap much longer, bouncing around, hitting the receptors over and over again.

So you have immediately, within hours, increased the concentration and effect of serotonin in the synapse.

But here we go again with the time lag.

The vacuum is clogged immediately, but the patient doesn't feel happy for two to four weeks.

Why?

It's what I call the brake pedal problem.

The text explains that on the presynaptic neuron, the one that sends the signal, there are special receptors called autoreceptors.

What do they do?

Think of them as sensors.

Their job is to measure how much serotonin is in the gap.

When they sense all that extra serotonin floating around because of the drug, they think, whoa, way too much signal out here.

We need to shut down.

So they hit the brakes.

They tell the neuron to stop firing and releasing serotonin.

Correct.

So the drug is increasing serotonin in the gap, but the brain responds by releasing less of it.

Initially, they almost cancel each other out.

So what changes over those two to four weeks?

After a few weeks of being constantly bombarded with high levels of serotonin, those autoreceptors, the brakes, get worn out.

They down regulate.

The cell literally pulls them off its surface.

The brakes disappear.

The brakes disappear.

And once the brakes are gone, the neuron starts firing at full speed again and the vacuum cleaner is still clogged.

That's when you finally get the massive surge in serotonin signaling that is thought to lift the depression.

The text also mentions a newer idea, neurogenesis.

Yes.

This is more modern twist on the theory.

There's growing evidence that these drugs might actually trigger the brain to grow new neurons, particularly in the hippocampus, a brain region crucial for mood and memory.

So we aren't just adjusting the chemical fluid levels.

We might actually be repairing the hardware of the brain.

That's the hope.

Yes.

Okay.

Let's get into the specific classes of antidepressants.

Segment five starts with the old classics, the tricyclic antidepressants or TC days.

Amitriptyline imipramine.

These are the first generation antidepressants.

I like to think of them as 1950s muscle cars.

How so?

They are very powerful, but they have absolutely no safety features and they pollute everything.

Explain the engine and the pollution.

The engine is that they block the reuptake of both serotonin and norepinephrine.

So they are very effective.

That's the powerful part.

But the pollution is that they also block muscarinic, alpha adrenergic, and histamine receptors.

Ah, so the side effects are the same as the low potency antipsychotics we just talked about?

Pretty much identical.

Dry mouth, constipation, sedation, dizziness, weight gain.

But the real defining danger with TCAs is overdose.

Right.

The text emphasizes this point heavily.

It's critical.

A depressed patient is by definition at risk for suicide.

If that patient takes a whole bottle of a modern SSRI, they will probably just vomit and feel terrible.

If they take a whole bottle of amitriptyline, they will die.

How does it kill you?

Cardiac toxicity.

The drug blocks sodium channels in the heart muscle.

On an EKG, you see a characteristic wide QRS complex.

The heart's electrical rhythm destabilizes and it just stops.

Is there an antidote?

Yes, and you need to know it.

The treatment for TFA overdose is sodium bicarbonate.

You're basically overwhelming the heart with sodium to compete with the drug and knock it off the channels.

Because of that overdose danger, we invented the SSRIs.

Selective serotonin reuptake inhibitors.

Crozac, Zoloft, Sitalopram, peroxetine, the modern sedans.

Why are they so much safer?

Because they are selective.

They're designed to only block the serotonin vacuum cleaner, the SERT protein.

They leave the other receptors, muscarinic, histamine, alpha alone.

So you don't get the dry mouth or the sedation or, most importantly, the heart stopping.

But they're not without their own issues, of course.

No drug is.

The text highlights three big ones for SSRIs.

Nervousness or agitation, insomnia, and the big one.

Sexual dysfunction.

How common is that?

Very.

The text notes that sexual dysfunction, loss of libido, impotence, the inability to orgasm is a major, major reason people stop taking their medication.

And the text points out some specific nuances for each individual SSRI.

For fluoxetine or Prozac.

The key thing there is its massive half -life.

It has an active metabolite that stays in your system for days, even weeks.

Which could be good if you forget a pill.

It's good for adherence, but it's bad if the drug is causing a side effect or if you need to switch medications quickly.

You have to wait a very long time for it to wash out of your system.

And what about Sitalopram?

That one has a specific cardiac warning.

The FDA has restricted the maximum dose because it can prolong the QT interval on an EKG.

Which can lead to that fatal rhythm, torsade de pointes.

Exactly.

It's a risk.

So the dose has to be managed carefully.

Then we have a class that's sort of a hybrid.

The SNRIs.

Serotonin and norepinephrine reuptake inhibitors.

Diloxetine and venlafaxine are the big ones here.

Think of these as a cleaner, modern version of the old TCAs.

They boost both serotonin and norepinephrine.

But without blocking all those dirty receptors.

Correct.

You get the dual action benefit without the TCA pollution.

But the key clinical takeaway for SNRIs, the thing that really sets them apart, is their use in chronic pain.

Why would an antidepressant stop pain?

It turns out that norepinephrine pathways descending from the brain down the spinal cord actually modulate and inhibit pain signals coming up from the body.

So by boosting norepinephrine, you're strengthening the body's own pain blocking system.

You got it.

That's why a drug like diloxetine, brand name Cymbalta, is a first line treatment for things like fibromyalgia and diabetic neuropathy.

It treats the depression and the pain at the same time.

Moving to segment 6, the text presents this next class as almost a last resort.

The nuclear option.

The MAOIs.

Monoamine oxidase inhibitors.

These are the last resort for treatment resistant depression for a very good reason.

Drugs like phenylzine and crenylsipramine.

Your mechanism is totally different, right?

Completely.

Instead of blocking the vacuum cleaner, they destroy the incinerator.

Monoamine oxidase is an enzyme that lives inside our mitochondria, and its job is to chew up and degrade any excess neurotransmitters.

Serotonin, norepinephrine, and dopamine.

And these drugs?

They bind to that MAO enzyme irreversibly and break it.

They kill it.

So the neurotransmitters just pile up and up and up.

Massive increases across the board.

But because MAO is an enzyme that works all over your body, not just in your brain, disabling it causes the famous and very dangerous cheese reaction.

This is a classic board exam question.

Can you explain the dinner party of death?

Absolutely.

So imagine you are on an MAOI.

You go to a party and you have a charcuterie board with aged cheese, cured salami, maybe you drink some red wine.

All of these foods are rich in a substance called tiramine.

Okay.

Normally the MAO enzyme in your gut and liver would destroy that tiramine before it ever got into your bloodstream.

But you've destroyed your MAO.

So the tiramine gets absorbed?

The tiramine gets into your blood, travels to your nerve endings, and acts as a powerful sympathomimetic agent.

It forces all of your stored norepinephrine to be dumped into the synapse all at once.

And the result of that is?

A hypertensive crisis.

Your blood pressure skyrockets.

You get a splitting headache, a stiff neck, nausea, and you can have a stroke and die.

It's a dietary landmine.

That's why we so rarely use them.

Let's talk about the atypical antidepressants that don't really fit the other molds, the propion or wellbutrin.

The propion is a weird one.

It doesn't touch serotonin at all.

It's a weak inhibitor of dopamine and norepinephrine reuptake.

And its main selling point?

Because it doesn't touch serotonin, it has N -no sexual side effects.

That is its biggest claim to fame and why it's often chosen for patients who can't tolerate that side effect from SSRIs.

It has other uses too, right?

Yes.

It's stimulating so it can help with the fatigue of depression and it's also licensed for smoking cessation under the brand name Zyben.

But there's a big risk?

Seizures.

It significantly lowers the seizure threshold.

The text is clear.

You never give this drug to a patient with a history of epilepsy or an eating disorder like bulimia or anorexia.

Why eating disorders?

Because the purging and malnutrition can cause electrolyte imbalances that already make them prone to seizures.

But propion would push them over the edge.

How about mirtazapine?

Mirtazapine is a tetracyclic.

Its mechanism is blocking alpha -2 auto receptors.

Remember how we said auto receptors are the breaks on the neuron?

Mirtazapine cuts the brake line immediately.

This causes a rapid and robust release of both norepinephrine and serotonin.

And its side effect profile is actually useful sometimes.

It is.

It is very sedating and causes significant weight gain.

This makes it a perfect choice for an elderly depressed patient who can't sleep and is losing weight.

It solves three problems with one pill.

And trazodone.

Trazodone is now used almost exclusively as a sleeping pill at low doses.

It's highly sedating.

It has a rare but very memorable side effect you have to know for exams.

Priapism.

Priapism.

A painful prolonged direction that doesn't go away and is a medical emergency requiring a trip to the ER.

We have to drop a major safety flag here for all these drugs.

Serotonin syndrome.

This is what happens if you combine these drugs recklessly.

If you take an SSRI and an MAOI together, or an SSRI and a migraine medicine called atriptan,

you can flood the brain with a toxic amount of serotonin.

And the symptoms are?

The patient becomes extremely agitated, confused, their muscles become rigid, and their temperature spikes hypersermia.

They can have seizures and they can die.

How do we prevent this?

With a washout period.

If you are stopping an SSRI to start an MAOI, you must wait at least two weeks for the SSRI to completely leave the body.

And there's an exception.

For Phloxedine or Prozac, because of that incredibly long half -life we talked about, you must wait five weeks.

It's a critical safety rule.

Okay, that covers depression.

Let's move to segment seven.

Bipolar disorder.

Here, the goal isn't just to lift mood, but to stabilize it.

Right, if you just give a standard antidepressant to a patient with bipolar disorder, you might overshoot the mark and push them straight into a full -blown manic episode.

So you need a ceiling and a floor.

Exactly.

And the gold standard, the classic treatment, is lithium.

It's literally just an element on the periodic table.

Lie plus a simple salt.

It is.

It's a piccation, just like sodium or potassium.

We still don't understand it completely, but the text highlights its effect on the inositol phosphate pathway, or IP3.

Can you break that down for us, the IP3 pathway?

Sure.

Think of the neurotransmitter, like serotonin or nerepinephrine,

as a mailman ringing the doorbell on the outside of the neuron.

The second messenger system, which includes IP3, is like the butler inside the house.

The butler hears the bell, runs to the kitchen, and tells the chef to start cooking.

That's the neuron activating.

And what does lithium do in this analogy?

Lithium breaks the enzymes that recycle the butler.

So the doorbell rings, but there's no butler available to answer it.

The signal doesn't get through as strongly.

So it dampens the neuronal excitement.

It turns down the volume.

That's a perfect way to put it.

It dampens the overactive signaling that leads to mania.

But lithium is a notoriously dangerous drug.

It has a very, very narrow therapeutic index.

The book gives the ranges 0 .6 to 1 .2 milliaeql.

What does that mean?

It means that below 0 .6, it doesn't work.

And if the level gets above 1 .5, you start to see serious toxicity, confusion, coarse tremors, EKG changes, and eventually seizures and coma.

There's very little room for error.

And the side effects reflect its similarity to sodium, right?

Absolutely.

The kidney handles lithium, and it can sometimes get confused between lithium and sodium.

The classic side effects are polyuria, the kidney loses its ability to concentrate urine, so the patient pees constantly.

And then drinks constantly to keep up.

Yes, polygypsia, also a fine hand tremor, and or the long -term hypothyroidism.

And the interaction warning is critical.

Absolutely critical.

Anything that makes the kidney hold on to sodium will also make it hold on to lithium, potentially pushing the levels into the toxic range.

Like what?

The two big culprits are diuretics, like hydrochlorothiazide for blood pressure, and common NSAIDs, like ibuprofen or Advil.

So a patient on lithium who takes Advil for a headache for a few days could actually poison themselves.

They can send themselves into acute lithium toxicity and kidney failure, yes.

It's a very dangerous interaction.

If a patient can't tolerate lithium, what are the other options?

We often turn to anti -epileptic drugs.

The text highlights Velprote, which is particularly good for patients who are rapid cyclers, meaning they switch between mania and depression frequently.

And carbamazepine.

Carbamazepine is another good option.

They both work by dampening neuronal firing just through different mechanisms than lithium.

All right, our final segment,

ADHD and the CNS stimulants.

Attention deficit hyperactivity disorder.

We primarily treat it with amphetamines like Adderall and methylphenidate like Ritalin.

The paradox here always gets people.

You have a hyperactive kid who is bouncing off the walls.

Why on earth would you give them a stimulant?

It sounds completely wrong, doesn't it?

But you have to remember where in the brain the drug is working.

It's stimulating the prefrontal cortex.

The brain's CEO.

Exactly.

The CEO, the executive control center.

In ADHD, the theory is that the CEO is asleep at the desk.

So all the employees, the impulses, the distractions, the random thoughts are running wild in the office.

And the stimulant is like a cup of coffee for the CEO.

It's a massive cup of coffee.

It wakes up the CEO.

Now the CEO is alert and say, hey, you sit down.

You focus on this task.

Everyone else, ignore that noise outside.

By stimulating the brain's control center, you paradoxically inhibit all the impulsive hyperactive behavior.

And the mechanism of how they work is a little different between the two.

It is.

Amphetamines are more aggressive.

The text explains that they actually enter the neuron and reverse the reuptake pump, forcing it to pump dopamine and norepinephrine out into the synapse.

And methylphenidate?

Methylphenidate is a bit milder.

It just blocks the reuptake pump like an SSRI does for serotonin.

It prevents the cleanup rather than actively pumping out more.

There is a non -stimulant option mentioned in the text, atomoxetine.

Atomoxetine is a selective norepinephrine reuptake inhibitor.

It takes weeks to work, unlike Ritalin, which works in 30 minutes.

But, and this is a huge but, it is not a controlled substance.

Because it has no abuse potential.

Exactly.

It doesn't really affect dopamine, so it doesn't produce a high.

This is a crucial option if you are treating a patient who has a personal or family history of substance addiction.

And the adverse effects of the stimulants?

Well, they're stimulants.

So, increased heart rate and blood pressure, insomnia, loss of appetite.

In children, the big concern we monitor is growth suppression.

Because they stop eating.

The anorexia, or loss of appetite, can be significant.

If a child isn't eating enough, it can stunt their growth.

So you have to monitor their height and weight charts very carefully.

And of course, because they release dopamine, they have a high potential for abuse and addiction.

Wow.

That was a journey.

From the shattered reality of schizophrenia to the molecular breaks of lithium.

It's a lot to take in.

But if you zoom out, as the chapter does, you see a consistent theme.

The theme is balance.

Explain that.

Schizophrenia is too much dopamine in one place.

We block it.

Depression is too little serotonin.

We boost it.

Bipolar is an unstable signal.

We dampen the second messenger.

And ADHD is a sleepy control center, so we wake it up.

It's all about restoring a chemical balance.

The brain is a chemical tightrope walker.

And these drugs are the balancing pole.

That's a great way to think about it.

And remembering the specific name side effects, the cheese reaction, the granulocytosis, the tardive dyskinesia, reminds us that the balancing pole is very, very heavy.

These drugs carry profound risks.

Thank you for walking that tightrope with us today.

To you, the learner who's listening,

go back and look at the tables and figures in chapter 22.

Visualize that vacuum cleaner.

Visualize the butler.

It really does make a difference.

Absolutely.

Stay critical, keep asking questions, and keep learning.

We'll catch you on the next Deep Dive.